The Impact of New Biomarkers and Drug Targets on Age-Related Disorders

Guest, Paul C.

doi:10.1007/978-1-0716-0471-7_1

Cited by 2 publications

(2 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 70 The identification of MCI-to-AD converters before the disease advances to the AD stage is also essential because the AD-associated loss of gray matter is effectively irreversible, so intervening prior to the loss of massive numbers of neurons is more likely to provide lasting, meaningful clinical benefits. 71 …”

Section: The Clinical Utility Of Mathematical Modelsmentioning

confidence: 99%

Connectome-based biophysics models of Alzheimer’s disease diagnosis and prognosis

Torok¹,

Anand²,

Verma³

et al. 2023

Translational Research

View full text Add to dashboard Cite

Section: The Clinical Utility Of Mathematical Modelsmentioning

confidence: 99%

Connectome-based biophysics models of Alzheimer’s disease diagnosis and prognosis

Torok¹,

Anand²,

Verma³

et al. 2023

Translational Research

View full text Add to dashboard Cite

“…A search is under way to identify biomarkers and immune function indicators to try and understand how older adults' immune responses help (or hinder) in fighting off the illness. These include biomarkers associated with inflammation, endothelial function, mitochondria and apoptotic function, calcium homeostasis, fibrosis, neuromuscular function, sarcopenia, and bone/hormone metabolism and nutritional status [21,22]. Again drawing from experience on influenza, while it is well known that older people are not well-protected by current influenza vaccines, what is less understood is that frailty is an important predictor of vaccine effectiveness against influenza-related hospitalization [17].…”

Section: Can Biomarkers Predict Covid-19 Severity?mentioning

confidence: 99%

COVID-19, frailty and long-term care: Implications for policy and practice

Andrew

Searle

McElhaney

et al. 2020

J Infect Dev Ctries

View full text Add to dashboard Cite

Older adults have been disproportionately affected by the COVID-19 pandemic, with many outbreaks occurring in Long Term Care Facilities (LTCFs). We discuss this vulnerability among LTCF residents using an ecological framework, on levels spanning from the individual to families and caregivers, institutions, health services and systems, communities, and contextual government policies. Challenges abound for fully understanding the burden of COVID-19 in LTCF, including differences in nomenclature, data collection systems, cultural differences, varied social welfare models, and (often) under-resourcing of the LTC sector. Registration of cases and deaths may be limited by testing capacity and policy, record-keeping and reporting procedures. Hospitalization and death rates may be inaccurate depending on atypical presentations and whether or not residents’ goals of care include escalation of care and transfer to hospital. Given the important contribution of frailty, use of the Clinical Frailty Scale (CFS) is discussed as a readily implementable measure, as are lessons learned from the study of frailty in relation to influenza. Biomarkers hold emerging promise in helping to predict disease severity and address the puzzle of why some frail LTCF residents are resilient to COVID-19, either remaining test-negative despite exposure or having asymptomatic infection, while others experience the full range of illness severity including critical illness and death. Strong and coordinated surveillance and research focused on LTCFs and their frail residents is required. These efforts should include widespread assessment of frailty using feasible and readily implementable tools such as the CFS, and rigorous reporting of morbidity and mortality in LTCFs.

show abstract

The Impact of New Biomarkers and Drug Targets on Age-Related Disorders

Cited by 2 publications

References 155 publications

Connectome-based biophysics models of Alzheimer’s disease diagnosis and prognosis

Connectome-based biophysics models of Alzheimer’s disease diagnosis and prognosis

COVID-19, frailty and long-term care: Implications for policy and practice

Contact Info

Product

Resources

About